Kornimate/medical-research-clean huggingface dataset:
microbiome and the gut-brain axis

Conditions: Mental Disorder

Summary: this research study will examine the relationship interconnecting medical body health, mental health, and microbes of the digestive tract in persons living with serious mental illnesses,as compared to persons without such disorders. existing research suggests that interactions between digestive tract microbes and the body may influence brain function circuits, mood, anxiety state, cognition, behavior, and medical physiology.

people living with serious mental illnesses have far shorter life expectancy due to various attending medical disorders. vast knowledge gaps exist regarding microbial taxa responsible for governing various the human states of health or morbidity or interactions with medications. serious mental illnesses collectively comprise the single largest medical category of life-long disability worldwide. mounting evidence in humans and in animal models of schizophrenia, post-traumatic stress disorder (ptsd) and related mental illnesses point to gut microbiome-host interactions that may influence brain function circuits, mood, anxiety state, cognition, behavior, as well as generate medical comorbidities. this research study will collect stool samples and blood for in vitro analysis of microbiome and metabolomics.

Eligibility criteria:
inclusion criteria: * people with an existing major mental illness, as already diagnosed currently or within the past year by their doctor prior to being consented, * meeting criteria of the fourth or fifth edition of the diagnostic and statistical manual of mental disorders (dsm-iv or dsm 5) or icd-9 or icd-10; * diagnosed with a cardiovascular disorder. exclusion criteria: * probiotic use currently or within 2 months prior to study enrollment, * antibiotic treatment currently or within 2 months prior to study enrollment; * diagnosis of an intellectual disability, pervasive developmental disorder, and/or progressive dementias including alzheimer's disease.

Keywords: gut microbiome mental disorder dysbiosis
a study to evaluate the pharmacokinetics and the safety after administration of br1015 and co-administration of br1015-1 and br1015-2 under fasting conditions

Conditions: Essential Hypertension

Summary: the purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of br1015 and co-administration of br1015-1 and br1015-2 in healthy volunteers under fasting conditions


Eligibility criteria:
inclusion criteria: * those weigh 50 kg or more and have body mass index (bmi) within the range of 18.0 to 30.0kg/m2 at screening visit. * those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the investigational products, expected adverse events, etc. * those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception accepted in clinical trial\*(except for hormone drugs) from the date of consent to 14 days after the last administration and disagrees to provide their sperm or ovum. * methods of contraception accepted in clinical trial: combined use of non hormonal intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, contraceptive diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used. exclusion criteria: * those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken drugs concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as interaction of investigational products, half-life of concomitant drugs, etc.) * those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months prior to the first administration date.(however, the termination for participation in other clinical trials are based on the last administration date of their investigational products) * those who have a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs. (except for simple appendectomy, hernia surgery) * those who can't discontinue a diet (ex. raw grapefruit, grapefruit juice or food containing grapefruit, etc.) that may affect the absorption, distribution, metabolism, and excretion of the drug within 48 hours prior to the first day of administration. * in the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman.
home safety intervention

Conditions: Suicide; Firearm Injury; Overdose

Summary: access to lethal methods of self-harm such as firearms and medications increases risk for suicide. as such, va/dod guidelines for the care of individuals with elevated suicide risk include recommendations that clinicians deliver interventions to reduce access to lethal methods of suicide among patients who are identified as having elevated suicide risk. however, no interventions have been developed or tested among veterans with elevated suicide risk. the aim of this study is to pilot test a lethal means safety intervention developed specifically for veterans who seek care in vha clinical settings and are identified as having elevated suicide risk.

the investigators will pilot the lms intervention among up to 50 veterans to assess feasibility and acceptability.

Eligibility criteria:
inclusion criteria: * encounter at vha ed or urgent care setting, outpatient mental health, women's health, or primary care -\>17 years * discharged home from the encounter (rather than hospital admission) * positive columbia screener * patient-reported access to self-owned firearms and/or medications exclusion criteria: * unable to consent due to cognitive impairment, severity of illness (including psychiatric symptoms), intoxication with drugs and/or alcohol * unreliable telephone access * unreliable video access (because remote intervention) * those currently experiencing unsheltered homelessness * no mailing address * active opioid or stimulant use disorder * active alcohol use disorder with daily alcohol consumption

Keywords: firearm
china pulmonary vascular disease intervention diagnosis and management study-right heart catheterization

Conditions: Pulmonary Hypertension; Pulmonary Embolism (Diagnosis); Pulmonary Arterial Hypertension; Right Heart Catheterization

Summary: right heart catheterization(rhc) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(pvd). in china, the lack of equipment and technical expertise has historically limited the implementation of rhc, thereby greatly restricting the diagnosis and treatment of rvd. in recent years, with improvements in these issues, more hospitals have acquired the capability to perform rhc. the purpose of this study is to conduct quality control of rhc across multiple pulmonary hypertension(ph) centers in china. the study population consists of patients who underwent rhc for the first time due to dyspnea or suspected ph. this study retrospectively and prospectively collects multicenter rhc data, with the main quality control contents including indications for the procedure, collection and analysis of hemodynamic data, diagnosis and treatment, and long-term management of patients.

this study is led by the china-japan friendship hospital and will be conducted across approximately 30 pulmonary hypertension centers in china. it is an observational cohort study without interventional treatment. eligible participants are patients aged 14 years or older who undergo right heart catheterization due to dyspnea or suspected pulmonary hypertension. after study initiation, investigators at each center will enroll eligible patients and collect baseline data, hemodynamic parameters from right heart catheterization, diagnostic classification of pulmonary hypertension, and treatment plans. patients will receive routine follow-up at their respective centers, and investigators will gather follow-up data according to the study protocol. all de-identified data will be recorded in an electronic data capture (edc) system. a dedicated data management team will oversee data management, quality control, and statistical analysis.

Eligibility criteria:
inclusion criteria: * patients who underwent right heart catheterization for the first time due to dyspnea or suspected pulmonary hypertension * age ≥14 years old exclusion criteria: * vital data missing * did not sign informed consent or did not agree to follow-up

Keywords: right heart catheterization pulmonary hypertension pulmonary arterial hypertension pulmonary vascular disease
use of two dissolvable therapeutics under removable partial dentures

Conditions: Edentulous Jaw; Edentulous Mouth

Summary: older removable denture wearing adults suffer from a complex set of oral health challenges, with relatively few solutions identified at this time. this is substantiated by statistics concerning the geriatric population on the correlation of poor oral health and the degradation of an individual's overall quality of life. the most recent national health and nutrition examination survey data found that 1 in 8 u.s. adults over the age of 65 are completely edentulous. a shift from complete edentulism to partial edentulism was also seen in this survey data, as the average individual over 65 had only 21 teeth remaining. thus, partial edentulism remains a significant burden on seniors as well. clearly, there exists both a great need and desire for improved implementation of proven oral-health strategies among this population, as well as the development of new preventive interventions and minimally invasive treatment strategies beyond traditional denture adhesive products. this proposed clinical trial intends to investigate two such potential treatment aids. in follow-up from our recent pilot study investigating mi paste's application on the intaglio of complete dentures, in which our current findings have shown that the use of mi paste can predictably increase the buffering capacity of a patient's saliva, our current proposal targets to further increase the study's sample size to improve the statistical power regarding subjective patient reports. the primary aims of this proposed study are to collect further data on how mi paste affects patients' subjective evaluations of the comfort and retention of their denture, as well as dry mouth symptoms in patients reporting xerostomia. furthermore, this study will include a second therapeutic intervention, biotene dry mouth gel (otc), which will provide an additional contrast variable involving patient preferences regarding therapeutics under their removable prostheses. we hypothesize that the use of both therapeutics underneath removable dentures will provide added retention and stability to the prosthesis on patient reports, further coinciding with improved evaluations of comfort and function. additionally, we hypothesize that the subjective improvements in patients self-reporting xerostomia will be of a statistically greater magnitude than those noticed by patients with normal salivary function, as xerostomia has been associated with increased denture discomfort in past literature.


Eligibility criteria:
inclusion criteria: * age 18-99 * patients with a removable prosthesis (e.g., partial denture, complete denture) * removable prosthesis must have been made at the university of iowa college of dentistry's department of family dentistry clinic within the past 10 years. exclusion criteria: * casein (i.e., protein found in milk or other dairy products) allergy * lactose intolerance * multiple food or cosmetic ingredient allergies in their health history * ill-fitting dentures that need to be remade or relined
3d hd versus 2d hd in cholecystectomy

Conditions: Cholelithiasis; Gall Bladder Disease

Summary: the aim of this study is to compare 3d-laparoscopy versus 2d-laparoscopy with the use of hd resolution in cholecystectomy in terms of error rating, performance time and subjective assessment.

conventional laparoscopy can be very challenging, especially with the requirement of converting the two-dimensional image of the operating field to a three-dimensional perception. this can potentially lead to a detrimental effect on the learning curve as well for the feasibility of the operation for the more inexperienced surgeon. in our hospital, the high frequency of cholecystectomy serves as a basis for the minimally experienced surgeons to explore whether three-dimensional laparoscopy provides a better ability for solving complex intraoperative tasks than the conventional laparoscopy.

Eligibility criteria:
inclusion criteria: * patients scheduled for elective cholecystectomy (out-patient treatment) exclusion criteria: * previous upper abdominal surgery * asa-score 3 or above

Keywords: 3d three-dimensional laparoscopy cholecystectomy
efficacy and safety of lymphdiaral basistropfen (hdc) in the treatment of chronic low-back pain

Conditions: Low Back Pain

Summary: to evaluate superiority of hdc in comparison to placebo in the treatment of chronic low-back pain in relation to pain, functional impairment, quality of life, and state of health during a 15-week treatment period.

low-back pain is often provoked by inflammatory edema in the region of the facet joints. in naturopathy, a fixed homeopathic drug combination (hdc) is established in the treatment of edema and swellings. for the first time, the efficacy of hdc was investigated in the treatment of low-back pain. objective: to examine the efficacy and safety of hdc medication vs. placebo in the treatment of chronic low back pain considering constitution and diathesism in a double-blind, randomized controlled clinical trial.

Eligibility criteria:
inclusion criteria: * male and female patients * aged 18 - 75 years * chronic low-back pain lasting at least for 6 months * hanover functional ability questionnaire (ffbh-r) score less than 70% * at least one of the following diagnoses: 1. chronic lumbar ischialgia with or without radicular radiation 2. chronic degenerative lumbar syndrome 3. spondylarthrosis 4. chronic facet syndrome 5. lumbago with protrusion of the intervertebral disc 6. lumbar radiculopathy 7. lumbar and other intervertebral disc impairments with radiculopathy 8. back pain at different locations of the spine * written, informed consent exclusion criteria: * participation in another clinical trial/gcp-trial within 30 days prior to screening * participation in this trial in an earlier time * treatment with lymphdiaral basistropfen within 3 month prior to enrolment * pregnancy and lactation * non-compliance * incapability to understand the sense of the study * abuse of analgesics, opiates or other drugs * chronic pain that are as strong as or even stronger than the pain caused by the low-back and that need to be treated with analgesics * malign diseases * pathological neurological states * epilepsy * operation of the spine within 3 month prior to enrolment * fractures of the spine * bechterew's disease * alcohol abuse * consuming diseases * cachexia * palsy of the legs or anal sphincter due to acute impairment of the intervertebral disc * catheterisation or ct-controlled intra-articular injection in the lumbar region * hypersensitivity against one of the ingredients or excipients of the study drugs or against composite plants in general * systemic, progressive diseases like tuberculosis, leucosis, collagenosis, multiple sclerosis, acquired immune deficiency syndrome (aids), human immunodeficiency virus (hiv) infection, or other auto-immune diseases

Keywords: low-back pain chronic constitution diathesism homoeopathy fixed combination herbal preparation chronic low back pain lasting more than 6 months
child asthma : what parents attitude during an asthma attack at home before consulting the pediatric emergencies

Conditions: Asthma in Children; Asthma Attack; Therapeutic Adherence

Summary: prospective multicenter observational study. parents whose children meet the inclusion criteria complete a questionnaire assessing the child's follow-up, the management of the current asthma attack, and the treatment provided at home. the main objective is to calculate the prevalence of placement of short-acting bronchodilators. the secondary objectives are to describe the factors associated with their implementation.


Eligibility criteria:
inclusion criteria: * child over 2 years emergency room consultant for asthma attack * child whose parents did not express their opposition to participate and completed the non-objection form * child consultant in pediatric emergencies of quimper and brest exclusion criteria: * child whose age is not between 2 and 15 years old * cough equivalent of asthma * history of cardiac or pulmonary pathology or prematurity * refusal to participate
comparing the efficacy of 14-day reverse hybrid therapy and 14-day triple therapy plus bismuth therapy

Conditions: Helicobacter Pylori Infection

Summary: reverse hybrid therapy achieves a higher eradication rate than bismuth (triple therapy plus bismuth) remains unanswered

with the rising prevalence of antimicrobial resistance, the failure rate of the 7-day standard triple therapy has declined to unacceptable level (\<80%) worldwide. several regimens were suggested to replace standard triple therapy in the area with high clarithromycin resistance, including sequential therapy, concomitant therapy, hybrid therapy and bismuth containing quadruple therapy. a 14-day hybrid therapy invented by our study group appears very promising in h. pylori eradication, achieving eradication rates of 95%. a clinical trial by hsu et al from our hospital showed 12-day reverse hybrid therapy also achieved high eradication rate, and improved the compliance of patients. even prolong the treatment duration of standard triple therapy from 7 days to 12 days, the efficacy of eradication was still \< 90% (85-88%). the limitation of triple therapy in against resistant-stains was still existed. the addition of bismuth (triple therapy plus bismuth) can improve cure rates despite a high prevalence of antimicrobial resistance. the major bismuth effect is to add an additional 30%-40% to the success with resistant infections. however the direct compare the efficacy between 14-day reverse hybrid therapy and 14-day triple therapy plus bismuth is still insufficiency in taiwan and worldwide. choosing a navel therapy or a modifying triple therapy can get better efficacy, it is remained to be determined. besides genotyping polymorphism of cyp2c19 influenced the metabolism of proton pump inhibit, and could cause decreasing of eradication rate of standard triple therapy. but the influence in 14-day reverse hybrid therapy and 14-day triple therapy plus bismuth is unclear.

Eligibility criteria:
inclusion criteria: * consecutive h pylori-infected outpatients, at least 20 years of age, with endoscopically proven peptic ulcer diseases or gastritis exclusion criteria: * previous h pylori-eradication therapy * ingestion of antibiotics or bismuth within the prior 4 weeks * patients with allergic history to the medications used * patients with previous gastric surgery * the coexistence of serious concomitant illness (for example, decompensated liver cirrhosis, uremia) * pregnant women

Keywords: helicobacter pylori eradication rate
a study of lanabecestat (ly3314814) in participants with mild alzheimer's disease dementia

Conditions: Alzheimer's Disease

Summary: the main purpose of this study is to evaluate the efficacy of the study drug known as lanabecestat in participants with mild alzheimer's disease (ad) dementia.


Eligibility criteria:
inclusion criteria: * participant must meet the national institute on aging (nia) and the alzheimer's association (aa) (nia-aa) criteria for probable ad dementia. * mmse score of 20 to 26 inclusive at screening visit. * for a diagnosis of mild ad dementia, participant must have a cdr global score of 0.5 or 1, with the memory box score ≥0.5 at screening. * evidence of amyloid pathology. * the participant must have a reliable study partner with whom he/she cohabits or has regular contact. exclusion criteria: * significant and/or current neurological disease affecting the central nervous system, other than ad, that may affect cognition or ability to complete the study, including but not limited to, other dementias, repetitive head trauma, serious infection of the brain, parkinson's disease, epilepsy, or cervicocranial vascular disease. * participants with any current primary psychiatric diagnosis other than ad if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessment, or affect the participant's ability to complete the study. participants with history of schizophrenia or other chronic psychosis are excluded. * within 1 year before the screening visit or between screening and randomization, any of the following: myocardial infarction; moderate or severe congestive heart failure, new york heart association class iii or iv; hospitalization for, or symptoms of, unstable angina; syncope due to orthostatic hypotension or unexplained syncope; known significant structural heart disease (such as, significant valvular disease, hypertrophic cardiomyopathy); or hospitalization for arrhythmia. * congenital qt prolongation. * intermittent second- or third-degree atrioventricular (av) heart block or av dissociation or history of ventricular tachycardia. * a corrected qt (qtcf) interval measurement \>470 milliseconds (men and women) at screening (as determined at the investigational site). * history of malignant cancer within the last 5 years. * history of vitiligo and/or current evidence of post-inflammatory hypopigmentation. * calculated creatinine clearance \<30 milliliters per minute (cockcroft-gault formula; cockcroft and gault 1976) at screening. * currently enrolled in any other clinical trial involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.

Keywords: dementia brain diseases neurodegenerative diseases central nervous system diseases nervous system diseases mental disorders delirium, dementia, amnestic, cognitive tauopathies memory amyloid